Nonalcoholic fatty liver disease (NAFLD)
Conditions
Interventions
None listed
Sponsors
Yokohama City University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: People who will receive a health checkup with abdominal US
Exclusion criteria
Exclusion criteria: 1. Alcohol consumption (ethanol equivalent volume), >=30 g/day for men, >=20 g/day for women, or >=210 g/day for men, >=140 g/day for women. 2. History of chronic hepatic disease (hemochromatosis, viral hepatic disease [hepatitis B or C], or autoimmune disease,[autoimmune hepatitis, primary biliary cholangitis]), thyroid disorder, lipoatrophy, parenteral nutrition, abetalipoproteinemia, alpha-1-antitrypsin deficiency, Wilson's disease, antiretroviral therapy, Reye's syndrome, HELLP syndrome, or inborn errors of metabolism (lecithin-cholesterol acyltransferase deficiency or lysosomal acid lipase deficiency) 3. Drug-induced liver disorder (amiodarone, methotrexate, tamoxifen, corticosteroids, valproic acid, and antiretroviral drugs)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the prevalence of NAFLD among people who receive a health checkup and elucidate the distribution of fibrosis stage in NAFLD patients by FibroScan | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To determine the proportion of patients with advanced fibrosis among NAFLD patients with a Fib4 index of <1.3 2. To determine how to set appropriate cutoff values of Fib4 index for each age category | — |
Countries
Japan
Contacts
Public ContactYuji Ogawa
Yokohama City University Department of Gastroenterology and Hepatology
Outcome results
None listed